| Generic Name: |
Pantoprazole
|
| Therapeutic Class: |
Gastrointestinal Agent
|
| Pharmacological Class: |
Proton Pump Inhibitor
|
| Composition: |
Each tablet contains Pantoprazole sodium 40 mg
(As delayed-release tablets)
|
| Pregnancy Category: |
B
|
| Presentation: |
Available in the pack size as 10 tablets X 20 strips
|
| Mechanism of action: |
Pantoprazole’s mechanism of action involves the permanent inhibition of proton pumps in the stomach, which are responsible for gastric acid production. It is a prodrug – in the acid environment of the parietal cells, Pantoprazole inhibits the H+, K+ ATPase of the coating gastric cells and gastric acid secretion is suppressed.
|
| Indications: |
- Gastro esophageal reflux disease (GERD)
- Heartburn
- NSAID induced gastritis
- Duodenal and Gastric ulcer
- Stress ulcer
- Zollinger-Ellison (ZE) Syndrome
- Hyper secretory Conditions
|
| Dosage: |
Route of administration: Oral
- GERD: 40 mg orally once a day 8 weeks
- Reflux esophagitis: 40 mg orally once a day for up to 8 weeks
- Gastric(stomach) Ulcer: 40 mg orally once a day for 4-8 weeks
- Duodenal(intestinal) Ulcer: 40 mg orally once a day for 12 weeks
- Zollinger Ellison Syndrome: 40 mg twice daily, to a maximum of 240 mg per day.
Better efficacy if taken 30 minutes before meal.
|
| Pharmacokinetics: |
- Absorption: Absolute bioavailability is approximately 77%.
- Protein binding: 98% (bound to human plasma proteins)
- Metabolism: Hepatic
- Route of elimination: Approximately 71% of the dose was excreted in the urine with 18% excreted in the feces through biliary excretion
- Half-life: 1 hour
|
| Adverse Effects: |
- Gastrointestinal: abdominal pain, diarrhea, flatulence, nausea, vomiting
- Neurologic: headache, dizziness
- Neuromuscular and skeletal: arthralgia
|
| Drug Interactions: |
Acidity: Due to its effect of reducing stomach acidity, use of pantoprazole can affect absorption of drugs that are pH-sensitive such as ampicillin esters, ketoconazole, atazanavir, iron salts, amphetamine and mycophenolate mofetil.
|